TNF and uveitis: Nevertheless, since inhibition of DHODH also impedes B cell activation, the therapeutic effect of KIO-100 (PP-001) exceeds an exclusive T cell suppression as gained by the presently approved therapies for uveitis, ciclosporin A and TNF-blocker Adalimumab (2).